आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
geepenil vet. stungulyfsstofn og leysir, lausn 24 g
orion corporation - benzylpenicillinum natríum - stungulyfsstofn og leysir, lausn - 24 g
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
strepsils med honning og citron munnsogstafla
reckitt benckiser healthcare (scandinavia) a/s - dichlorobenzylalcohol; amylmetacresolum inn - munnsogstafla
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
strepsils jordbær sukkerfri (strepsils sukkerfri med lemon og urter) munnsogstafla
reckitt benckiser healthcare (scandinavia) a/s - amylmetacresolum inn; dichlorobenzylalcohol - munnsogstafla
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
strepsils cool (strepsils med menthol og eucalyptus) munnsogstafla
reckitt benckiser healthcare (scandinavia) a/s - amylmetacresolum inn; dichlorobenzylalcohol - munnsogstafla
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
strepsils ingefær (strepsils warm) munnsogstafla
reckitt benckiser healthcare (scandinavia) a/s - amylmetacresolum inn; dichlorobenzylalcohol - munnsogstafla
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
epiduo hlaup 0,1 % / 2,5 %
galderma nordic ab - adapalenum inn; benzoylis peroxidum - hlaup - 0,1 % / 2,5 %
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
penovet vet. stungulyf, dreifa 300 .000 a.e./ml
boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum - stungulyf, dreifa - 300 .000 a.e./ml
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
carepen vet (caremast vet) spenalyf, dreifa 600 mg
vetcare oy - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
carepen vet spenalyf, dreifa 600 mg
vetcare ltd.* - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg
यूरोपीय संघ -
आइसलैंडी -
EMA (European Medicines Agency)
aubagio
sanofi winthrop industrie - teriflunomide - margvísleg sclerosis - valdar ónæmisbælandi lyf - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).